---
title: "Jazz Pharmaceuticals Shareholders Reaffirm Board and Governance Plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293744164.md"
description: "Jazz Pharmaceuticals shareholders reaffirmed board leadership by electing three directors and approved executive compensation and KPMG as auditors at the July 23, 2026 AGM. The board was granted authority to issue shares without pre-emptive rights, enhancing capital flexibility. Analysts rate JAZZ stock a 'Buy' with a $290 target, citing strong cash flow, high gross margins, and reasonable valuation, despite short-term overbought technical signals."
datetime: "2026-07-24T10:46:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293744164.md)
  - [en](https://longbridge.com/en/news/293744164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293744164.md)
generator: "portal-rs"
---

# Jazz Pharmaceuticals Shareholders Reaffirm Board and Governance Plans

Jazz Pharmaceuticals ( (JAZZ) ) has issued an update.

At its July 23, 2026 annual general meeting in Dublin, Jazz Pharmaceuticals’ shareholders elected three directors—Bruce C. Cozadd, Heather Ann McSharry and Rick E. Winningham—to serve until the 2029 annual meeting, signaling continuity in board leadership. Shareholders also approved, on an advisory basis, the compensation of the company’s named executive officers, reinforcing support for current management’s pay structure.

Investors ratified the appointment of KPMG Dublin as independent auditors for the fiscal year ending December 31, 2026, and authorized the board’s audit committee to set their remuneration, underscoring confidence in the company’s financial oversight. Shareholders further granted the board authority under Irish law to allot and issue ordinary shares, including for cash without pre-emptive rights, enhancing Jazz’s flexibility to raise capital or pursue strategic transactions without needing additional shareholder approvals; a contingency proposal to adjourn the meeting was not needed and was therefore not voted on.

The most recent analyst rating on (JAZZ) stock is a Buy  
 with a $290.00 price target.  
 To see the full list of analyst forecasts on Jazz Pharmaceuticals stock,  
 see the JAZZ Stock Forecast page. 

**Spark’s Take on JAZZ Stock**

According to Spark, TipRanks’ AI Analyst, JAZZ is a Outperform.

The score is driven primarily by strong cash-flow generation and sustained high gross margins, supporting financial resilience despite volatile net income. Technicals are constructive with a strong uptrend, though overbought signals raise short-term risk. Valuation appears reasonable with a ~10 P/E, and the latest earnings call was broadly positive with reaffirmed guidance, tempered by expected H2 sleep-market competition and some margin/mix pressure.

To see Spark’s full report on JAZZ stock,  
 click here. 

**More about Jazz Pharmaceuticals**

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for serious and often under-addressed diseases. The company’s portfolio spans neuroscience and oncology, with a particular emphasis on sleep medicine, movement disorders and hematologic malignancies, targeting niche markets with high unmet medical need.

**Average Trading Volume:** 875,772

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $15.73B

For an in-depth examination of JAZZ stock, go to TipRanks’ Overview page.

### Related Stocks

- [JAZZ.US](https://longbridge.com/en/quote/JAZZ.US.md)

## Related News & Research

- [Jazz Pharmaceuticals (JAZZ) Could Be 13% Undervalued On FDA Approval Of Ziihera](https://longbridge.com/en/news/297431759.md)
- [Jazz Pharmaceuticals Raises $1.25 Billion Via 1.875% Exchangeable Notes Due 2032](https://longbridge.com/en/news/297565380.md)
- [Jazz reports Phase III trial interim results for Ziihera combination](https://longbridge.com/en/news/298029886.md)
- [Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer](https://longbridge.com/en/news/297497068.md)
- [Jazz Pharma director Bruce C. Cozadd disposes of USD 1.79 million in ordinary shares](https://longbridge.com/en/news/297830909.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**